Autism Medical Cannabis Studies

• View All (505)

Alterations in the endocannabinoid system in the rat valproic acid model of autism (2013)

Prenatal exposure to valproic acid is associated with alterations in the endocannabinoid system of the brain. These results indicate that it is possible that endocannabinoid dysfunction may be the basis of behavioral abnormalities observed in autism spectrum disorders. View study
Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling (2013)

Neuroligin-3 is specifically necessary for tonic endocannabinoid signaling. This suggests that alterations in endocannabinoid signaling may contribute to the pathophysiology of autism. View study
Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders (2013)

At present there is no absolutely effective treatment for autism, in fact the curative therapy is very difficult. These studies reflect the cannabinoid receptor CB2 as a possibility for the therapy and pharmacological management of autism. View study
Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders (2011)

These experiments demonstrated the therapeutic potential of cannabinoids to help treat autism. View study
Deficient Social and Play Behavior in Juvenile and Adult Rats after Neonatal Cortical Lesion: Effects of Chronic Pubertal Cannabinoid Treatment (2004)

The medial prefrontal cortex (mPFC) contributes to the development of social behavior skills of adults, social motivation and personal hygiene. In addition, the results of this study suggest that the cannabinoid system has participation in anxiety and social behavior. View study
Endocannabinoid System as Novel Therapeutic Target for Autism Treatment (2014)

The results of this study offer new perspectives in the investigation of autism. In addition, they indicate that the endocannabinoid system could be an important goal in the pharmacotherapy of autism. View study
Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression (2012)

View study
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands (2009)

The results of this study suggest that the cannabinoid CB2-R could be involved in the mechanisms of endocannabinoid signaling associated with the regulation of emotionality. More studies are needed to determine if the CB2-R ligands increase the risk of depression or suicide (which led to the recall of Rimonabant as an appetite suppressant in the control of obesity). View study
Uncoupling of the endocannabinoid signaling complex in a mouse model of fragile X syndrome (2012)

The pharmacological potentiation of 2-arachidonoyl-sn-glycerol signaling normalizes the synaptic defect of depression and corrects behavioral abnormalities in mice with fragile X syndrome. The endocannabinoid signalosome is a molecular substrate for fragile X syndrome, which might be targeted by therapy. View study
Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child (2010)

In assessing the effectiveness of dronabinol as a complementary therapy in a child with autistic disorder, it was found that dronabinol can reduce the symptoms of autism. View study
Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces (2011)

CNR1 modulates striatal function through which social reward signals are perceived, such as happy faces. These results suggest that CNR1 is a key element in the perception process of certain basic emotions. View study